尽管季度亏损，Kodiak Sciences凭借视网膜药物试验的进展，仍飙升至12个月来最高点。 Kodiak Sciences surged to a 12-month high despite a quarterly loss, driven by progress in its retinal drug trials.

Kodiak Science(KOD)于2025年12月17日创下12个月28.79美元的高峰, 关闭28.05美元, Kodiak Sciences (KOD) hit a 12-month high of $28.79 on December 17, 2025, closing at $28.05, despite reporting a quarterly loss of $1.16 per share, missing estimates. 该生物制药公司在晚期对视网膜疾病进行试验时,正在推进其主要药物 -- -- 薄凝胶Tedromer(KSI-301)。 The biopharmaceutical company is advancing its lead drug, tarcocimab tedromer (KSI-301), in late-stage trials for retinal diseases. 机构所有权占89.06%,虽然分析师的评级从卖到买不等,但共识仍然是“坚持”,平均价格目标为22.67美元。 Institutional ownership stands at 89.06%, and while analyst ratings range from Sell to Buy, the consensus remains "Hold" with a $22.67 average price target. 股票的市场上限为14.7亿美元,P/E比率为负数,波动性很大。 The stock has a market cap of $1.47 billion, a negative P/E ratio, and high volatility.